FDA Orphan Approval Slowdown Meets G-BA Evidence Tightening: Access Corridor Narrows on Both Sides

FDA Shifts Stance on Rare Disease Approvals Post-Leadership Changes

The FDA is undergoing a significant shift in its approach to rare disease drug regulation, marked by leadership changes and a renewed commitment to fostering innovation. Despite a slowdown in orphan drug approvals in the first half of 2026, with only six approvals compared to 30 in the previous year, regulatory experts are optimistic about a turnaround. The departure of former CBER Director Vinay Prasad and Commissioner Marty Makary has led to a more collaborative stance from the agency, with acting Commissioner Kyle Diamantas engaging rare disease groups to repair relations and expedite previously stalled applications.

• The FDA approved only six orphan drugs in the first half of 2026, a notable decrease from 30 in 2025. CBER, which regulates gene therapies, approved two orphan drugs in H1 2026, compared to three to nine in previous years. This slowdown is attributed to a "lagging indicator" reflecting 2024 progress, with expectations for increased activity in H2 2026 and 2027.
• The departures of former CBER Director Vinay Prasad and Commissioner Marty Makary in April and May 2026, respectively, are seen as pivotal. Regulatory experts believe the FDA has since returned to a more "partner in innovation" role, moving away from a critical stance. Acting Commissioner Kyle Diamantas has actively sought to repair relations with the rare disease sector, indicating a willingness to recognize sponsors' equal voice in the process.
• Following the leadership changes, the FDA has reversed previous rejections and agreed to new pathways for several rare disease drugs. Examples include Disc Medicine's bitopertin, uniQure's Huntington's disease gene therapy (allowing three-year data for accelerated approval), and resubmissions from Replimune and Saol Therapeutics. These actions signal a more flexible and supportive regulatory environment for rare disease drug development.
• The second half of 2026 is expected to see multiple regulatory decisions and advisory committee meetings, including for previously rejected therapies. While the rare disease space is on an upswing, experts anticipate continued "tension" between scientific considerations and political influences within the FDA. The agency's focus under the Makary administration on accelerating rare disease therapies through new policies like the plausible mechanism pathway is expected to yield benefits in the long term.

How FDA Leadership Shifts Are Reshaping Rare Disease Approvals

Over the past five years, the rare disease treatment landscape has seen meaningful but uneven progress. The drug development pipeline is projected to yield approximately 45 new product approvals for pediatric-onset rare diseases by 2033, representing a 14% growth in annually treated patients and an incremental increase in list price drug revenues from $28.2B in 2023 to $38.9B in 2033. Recent regulatory milestones include the FDA approval of diazoxide choline for hyperphagia and obesity associated with Prader-Willi syndrome — a mechanistically novel agent that activates ATP-sensitive potassium channels in pancreatic beta cells, with downstream effects spanning apoptosis, inflammation, glucose metabolism, and appetite regulation. Despite these advances, the structural deficit in the field remains stark: as of 2022, 90–95% of more than 7,000 rare disease communities still lack an approved therapy, and 95% of pediatric-onset rare diseases are projected to remain without treatment options even a decade from now. The number of newly identified rare diseases continues to outpace the rate of therapeutic approvals.

Emerging modalities are beginning to reshape the clinical trial landscape, though most remain in early development. As of mid-2025, 557 clinical trials of mRNA-based therapeutics were registered across ClinicalTrials.gov and the Chinese Clinical Trial Registry, of which 22 specifically investigated rare disease indications. The majority of all mRNA trials were interventional (85.82%) and conducted across phases 0–3 (73.97%). Notably, among newly registered projects in 2024 and 2025, phase 0–1 trials accounted for 61.67% and 78.13% of registrations respectively, signaling a pipeline still heavily weighted toward early-stage investigation. Broader technological integration is also accelerating: multi-omics approaches combining genomics, transcriptomics, and epigenomics — analyzed through AI and machine learning tools — are increasingly being used to identify disease-relevant patterns and guide gene-editing strategies aimed at addressing root molecular causes.

Diagnostic delays and systemic infrastructure gaps continue to limit the real-world impact of therapeutic advances. The average diagnostic odyssey spans 5.4 years in Brazil and 6–8 years across European cohorts, with direct consequences for prognosis and treatment eligibility. In Brazil, drug therapy remains the primary treatment modality for 55% of rare disease patients, with the public health system funding 84.2% of diagnoses and 86.7% of treatments — reflecting heavy reliance on state infrastructure in lower-resource settings. Meanwhile, gene and cell therapy development timelines frequently span decades, creating a pace that remains fundamentally misaligned with patient urgency. Collectively, these data underscore that while scientific and regulatory momentum is building, the field faces a compounding challenge: accelerating therapeutic development against a backdrop of an ever-expanding rare disease taxonomy and persistent systemic barriers to timely diagnosis and equitable access.

Rare Disease Therapies Get a Second Look from the FDA

Recent rare disease research has yielded targeted interventions across a range of ultra-rare and complex conditions, with findings ranging from compassionate-use approvals to large-scale regulatory submissions. The studies below highlight distinct approaches — from computational drug repositioning to network-based clinical collaboration — each addressing the unique evidentiary challenges inherent to rare disease drug development.

• Menatetrenone (MK4) Repositioning for Infantile-Onset Ascending Hereditary Spastic Paralysis (IAHSP): In this single-patient study of an Italian IAHSP patient (AO) harboring the R1611W mutant ALSIN, menatetrenone (MK4) was evaluated using molecular dynamics simulations and skin fibroblast cell lines with advanced microscopy and automated image analysis. Key efficacy findings included rescue of Mean Branch Diameter and restoration of ALSIN levels in patient-derived fibroblasts, with elevated oxidative stress and a characteristic mitochondrial phenotype identified as cellular markers of disease. These results supported compassionate-use approval for a patient-specific therapeutic regimen.

• Diazoxide Choline for Prader-Willi Syndrome (PWS): Diazoxide choline, which acts by activating the ATP-sensitive potassium channel (KATP) of pancreatic beta cells to inhibit insulin release, was evaluated in a clinical trial for PWS — a genetically heterogeneous disorder with limited prior therapeutic advances. The FDA subsequently approved diazoxide choline for the treatment of hyperphagia and obesity associated with PWS. Four essential functional domains were identified as relevant to its mechanism: apoptosis, protein degradation, and inflammation; G-protein coupling required for KATP channel activation; glucose metabolism and control; and maintenance of intracellular ionic homeostasis. A key study limitation was the small sampling population, which may have been insufficient to adequately characterize adverse outcomes.

• Desidustat (DESI.23.001) Phase IIa Trial in Sickle Cell Disease: This double-blind, randomized, placebo-controlled, multicenter proof-of-concept trial enrolled 24 Indian adults with sickle cell disease across three dose cohorts of desidustat — an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) — at 50 mg, 100 mg, and 150 mg, randomized 3:1 (desidustat:placebo). The primary efficacy endpoint was hemoglobin response rate at week 8 relative to baseline versus placebo, with dose adjustment at week 4 guided by HemoCue-measured hemoglobin levels. The intervention stimulates erythropoietin production, promotes erythropoiesis, and improves iron metabolism to increase hemoglobin and RBC indices; formal safety outcome data had not yet been reported at the time of the protocol publication.

• Janus Kinase Inhibitor (JAKi) Development Across Rare Diseases (1995–2025): A systematic analysis identified 271 JAKi candidates across 2,035 associated clinical trials, with trial activity rising sharply since 2018. Phase III trials comprised 26% of studies, while 52% remained in early-phase (Phase I/II) research. Rare diseases accounted for 35.8% of all targeted indications and 20.4% of clinical trials, with immune-mediated inflammatory diseases (69.3%) and hematopoietic malignancies (14.0%) as the dominant therapeutic areas. While JAKi demonstrated substantial efficacy across autoimmune, inflammatory, and rare hematologic indications, key safety concerns included off-target effects on cellular signaling pathways and interindividual pharmacokinetic variability complicating optimal dosing regimen design.

Addressing Unmet Needs in the Evolving Rare Disease Landscape

Current treatment approaches for rare diseases face a constellation of structural, clinical, and systemic challenges that collectively impede timely diagnosis and equitable access to care. These barriers span healthcare infrastructure, regulatory frameworks, research capacity, and governance — and are particularly pronounced in low- and middle-income settings. Addressing these gaps requires coordinated action across clinical, policy, and research domains.

• Prolonged diagnostic odyssey: Delayed diagnosis remains a central problem in rare disease care, averaging 6–8 years, with serious implications for prognosis, treatment outcomes, and quality of life. Rare diseases may be asymptomatic until a relatively late stage, and 31% of researchers and 29% of healthcare professionals surveyed were unaware of the time required to diagnose a rare disease — reflecting systemic knowledge gaps across the care continuum.

• Underreporting and diagnostic invisibility: Many cases of rare diseases remain unreported, undiagnosed, and untreated, particularly in resource-scarce settings such as India, where healthcare infrastructure and policy frameworks are primarily oriented toward high-burden, high-prevalence conditions. The scarcity of disease registries — for example, the near-total absence of rare eye disease registries globally, and their complete absence in India — further compounds epidemiological blind spots.

• Limited clinical expertise and research infrastructure: Patients frequently encounter barriers to accurate diagnosis and treatment due to insufficient clinical expertise and inadequate infrastructure. Clinical evaluation of therapeutics is constrained by low disease prevalence, poorly characterized natural histories, and the inapplicability of standard postapproval safety tools such as meta-analyses and spontaneous adverse event reporting systems.

• Data scarcity in drug discovery: Drug development for rare diseases is impeded by the absence of tractable biophysical assays and validated in vivo models, limiting the ability to identify and advance therapeutic candidates through early-stage pipelines.

• Uneven access to innovative therapies: Access to approved treatments remains inequitable and constrained by high costs and fragmented health system arrangements, as evidenced across Latin America and the Caribbean. Regulatory approval does not consistently translate into timely or comprehensive coverage, and institutional capacity alone is insufficient to achieve broad, sustained therapeutic access.

• Governance and policy fragmentation: Globally, rare disease management is undermined by weak inter-organizational policy coordination, fragmented coverage schemes, barriers to drug accessibility, and underdeveloped data governance infrastructure. In China specifically, asymmetric allocation of medical resources across healthcare levels has hindered the establishment of a homogenized rare disease diagnosis and management system, and young physicians continue to face significant capability gaps in this area.

• Training and awareness deficits: Healthcare professionals demonstrate critical knowledge gaps — including failure to recognize the association between family history and geographic location in rare disease risk — underscoring the need for structured training in molecular diagnostics and genomic medicine, as well as a formalized national genomic medicine strategy in multiple geographies.

• Burden on patients, families, and primary caretakers: Rare diseases exert a substantial physical, emotional, and economic toll on patients and families. Primary caretakers bear a disproportionate coordination burden; implementation of structured diagnostic pathways could meaningfully reduce this burden, shorten time-to-diagnosis, and lower downstream costs to healthcare systems.